Replimune Reports $313.9M Net Loss and Faces Regulatory Challenges for RP1

Replimune Group, Inc., a clinical-stage biotechnology company focused on oncolytic immunotherapy, reported a net loss of $313.9 million for the fiscal year ending March 31, 2026, compared to a net loss of $247.3 million in the previous year, marking a 27% increase in losses. The company's total operating expenses rose to $319.9 million, a 22% increase from $261.6 million in the prior year, driven primarily by a 17% increase in research and development expenses, which totaled $221.2 million. This increase was largely attributed to heightened spending on clinical trials, particularly the RP2 study, and operational costs associated with the RP1 program.

In terms of strategic developments, Replimune has been actively pursuing regulatory approval for its lead product candidate, RP1 (vusolimogene oderparepvec), in combination with nivolumab for the treatment of advanced melanoma. The company submitted its first Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in November 2024, which was accepted for priority review. However, the FDA issued a complete response letter (CRL) in July 2025, stating that the application could not be approved in its current form. Following a resubmission in October 2025, the FDA issued a second CRL in April 2026, reiterating concerns about the adequacy of the clinical trial data. Replimune is currently working with the FDA to address these issues and plans to resubmit the BLA.

Operationally, Replimune employed 465 full-time employees as of March 31, 2026, although the company implemented a restructuring plan in April 2026, reducing its workforce by approximately 55% due to the uncertainty surrounding the approval of RP1. The company has also been expanding its clinical trials, including the IGNYTE-3 trial, which is a Phase 3 study for anti-PD-1 failed melanoma patients. The company reported that it has been ramping up patient enrollment in these trials, which is critical for the advancement of its product candidates.

Looking ahead, Replimune's financial outlook remains uncertain, as the company anticipates that its existing cash and cash equivalents, totaling $268.9 million as of March 31, 2026, will only sustain operations into the first quarter of 2027. The company has not generated any revenue from product sales to date and will require additional funding to continue its operations and development efforts. The need for further financing raises concerns about the company's ability to sustain its operations, particularly if the BLA for RP1 is not approved. Replimune's future success will depend on its ability to navigate these challenges and secure the necessary capital to support its ongoing clinical programs and potential commercialization efforts.